Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has agreed a settlement over its generic version of Cinacalcet HCl with Amgen Inc., which develops and markets the branded drug. Cinacalcet hydrochloride treats secondary hyperparathyroidism in adults with chronic kidney disease on dialysis. Annual sales of the branded drug amount to $1.7 billion. RELATED ARTICLES Teva will lease new 17-floor Tel Aviv HQ from Vitania Teva could be hit by huge fine on US cartel probe Teva, Celltrion win FDA approval for Rituxan biosimilar Teva begins selling generic EpiPen Teva has already launched its generic version but has agreed to stop marketing it until mid-2021 as part of the settlement. As part of the settlement, Teva will pay Amgen an undisclosed sum and this will end all legal proceedings on the matter. Published by Globes, Israel business news - en.globes.co.il - on January 3, 2019 © Copyright of Globes Publisher Itonut (1983) Ltd. 2019
